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Abstract
Sedatives and analgesics are routinely used in the intensive care
unit to relieve pain and anxiety. These agents have numerous side
effects and may contribute to poor outcomes such as increased
length of mechanical ventilation, longer ICU stays and acute and
long-term cognitive dysfunction. Modifying sedation paradigms
utilizing either narcotic-based regimens with remifentanil or
fentanyl, or by using α2 agonists such as dexmedetomidine may
help in improving these outcomes in critically ill patients.
Benzodiazepines and narcotics are an integral component of
the pharmacological treatment of millions of critically ill
mechanically ventilated patients. This month in Critical Care,
Breen and coworkers [1] report that narcotic-based sedation
strategies, compared with the traditional approach involving
benzodiazepines with supplemental analgesics for pain, might
have improved patient outcomes. In this prospective, randomized,
unblinded trial, target-based sedation with remifentanil and
rescue midazolam was associated with decreased duration of
mechanical ventilation and shorter times to extubation
compared with sedation with benzodiazepines, with rescue
fentanyl or morphine. The study has important ramifications in
the light of recent investigations that have questioned whether
currently used strategies for providing sedation and analgesia
in mechanically ventilated patients are optimal.
The Society of Critical Care Medicine, in its 2002 clinical
practice guidelines [2], recommended protocolized target-
based sedation. Those guidelines recommend the use of
lorazepam for long-term sedation and midazolam or propofol
for short-term sedation, with fentanyl or morphine for
analgesia. Unfortunately, benzodiazepines have numerous
adverse effects, including the potential for prolonged
ventilation, development of delirium and contribution to
chronic cognitive dysfunction [3-7]. Hence, modification to
delivery patterns of sedatives or changing sedation
paradigms could alter patient outcomes.
Prior studies [6,8-10] have demonstrated reductions in
duration of mechanical ventilation and intensive care unit
(ICU) length of stay with protocolized, target-based sedation
and daily wake-up trials, and by modifying the route of
administration of these drugs (intermittent versus continuous
infusion). Although sedatives and analgesics act on the
central nervous system, studies comparing sedative and
analgesic regimens have tended not to report neurological
outcomes. This was not possible until recently because of the
lack of monitoring tools that could measure outcomes such
as delirium in nonverbal patients. Newer reliable and validated
sedation scales such as the Sedation Agitation Scale,
Richmond Agitation Sedation Scale, and the Confusion
Assessment Method in the ICU for detecting delirium in
mechanical ventilated patients permit measurement of these
outcomes [11-14]. This is important because delirium is an
independent predictor of prolonged mechanical ventilation,
longer ICU stay and mortality [15].
Benzodiazepines and propofol act primarily as γ-aminobutyric
acid (GABA) agonists to exert their sedative effects. Along
similar lines, alcohol is an agonist at the GABA receptor,
which is believed to be the probable mechanism underlying
the cognitive impairment seen in alcoholic persons [16,17].
Use of novel agents that are GABA receptor sparing (e.g.
remifentanil at the µ opioid receptor or dexmedetomidine at
the  α2 receptors) may help to reduce exposure to benzo-
diazepines and consequently the degree of brain dysfunction,
and may improve outcomes such as duration of mechanical
ventilation and ICU length of stay.
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Remifentanil has been shown to be efficacious and safe in
critically ill patients [18]. It is an attractive agent for sedation
in the ICU because of its favorable pharmacokinetic and
pharmacodynamic profiles. The drug is metabolized by non-
specific plasma esterases and is therefore independent of the
function of organs such as the liver and kidneys. Studies in
critically ill patients [19,20] have demonstrated a predictable
and constant offset time, with little or no accumulation of drug
over time. However, there are conflicting reports on the
development of tolerance as well as withdrawal after
discontinuation of remifentanil [20-22]. Additionally, remifentanil
does not possess amnestic or anxiolytic properties.
The study reported in the present issue by Breen and
coworkers [1] was an unblinded study conducted in 10
countries and in 15 medical centers. Although the titration of
remifentanil was based on a fixed protocol, titration of the
comparator benzodiazepine infusion was left to the discretion
of the individual centers, based on local clinical practice.
Furthermore, even though there was no statistical difference in
the time from start of study drug to the beginning of the
weaning process, this process was begun in the remifentanil
group an average of 15 hours earlier. In addition, it is not clear
why the patients in the comparator benzodiazepine arm took
longer to be extubated once weaning was instituted. It would
be interesting to know whether the benzodiazepine group took
much longer to return to an acceptable level of arousal for
extubation or whether there were other confounding factors,
such as delirium, that delayed extubation in this group. The
authors do mention that the sedation levels were matched in
both groups, during treatment and in the post-treatment period,
and that the differences were due to the drug per se and not
the level of sedation. However, a physiological basis for this
difference is not offered. This is important in the context of an
unblinded trial, in which there is always the potential for bias.
What this field now needs is a new guard of studies focusing on
acute and long-term cognitive outcomes of sedative regimens in
addition to outcomes such as days on mechanical ventilation
and ICU length of stay. Modifying sedation paradigms by
utilizing agents such as remifentanil or dexmedetomidine may
provide clinicians with alternatives to the ‘gold standard’
benzodiazepines. However, for that to happen we need
rigorously conducted, blinded, randomized controlled trials.
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